Truist Securities Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $410

Benzinga Newsdesk www.benzinga.com Negative 61.3%

Neg 61.3% Neu 0% Pos 0%

Truist Securities analyst Danielle Brill maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $505 to $410.